Laboratorios Farmaceuticos Rovi
€57.80Change from previous close: +0.78%Absolute change: +€0.45
Valuation
Data as of October 2, 2026
Valuation multiples
- Market cap
- €2.96B
- Enterprise value
- €2.93B
- P/E (trailing 12 months)
- 16.0
- Forward P/E
- 17.2
- PEG
- 1.26
- Price/book
- 4.22
- Price/sales
- 3.82
- EV/EBITDA
- 16.6
- EV/revenue
- 3.79
Profitability and growth
- Gross margin
- 64.7%
- Operating margin
- 9.4%
- Net margin
- 24.0%
- ROE
- 28.7%
- ROA
- 9.4%
- Revenue growth (year over year)
- 20.0%
- Earnings growth (year over year)
- 246.7%
Financial health
- Total cash
- €128.07M
- Total debt
- €107.69M
- Debt/equity
- 0.15
- Current ratio
- 2.05
- Quick ratio
- 1.04
Dividends
- Annual dividend per share
- €0.96
- Dividend yield
- 1.7%
- Payout ratio
- 25.8%
- Ex-dividend date
- July 13, 2026
Analysts and estimates
- Average price target
- €74.36
- Median price target
- €75.00
- High price target
- €83.00
- Low price target
- €64.20
- Analysts with a price target
- 9
- Forward EPS
- €3.36
- EPS estimate, current year
- €2.47
Shares and trading
- Beta
- 0.24
- Average volume
- 114.49K
- Shares outstanding
- 51.14M
- Float
- 16.2M
- Institutional ownership
- 16.8%
- Insider ownership
- 68.2%